Disease Focus: Solid Tumors
Development of an AAV gene therapy immunotherapy for the treatment of glioblastoma
Translational Candidate SRN-101, an experimental AAV gene therapy for treating glioblastoma Area of Impact Cancer – solid tumors Mechanism of Action Following delivery with an AAV, engineered cytokines are expressed from within the tumor to kill the tumor from the inside out, they are then further secreted to stimulate local immune cells to kill remaining […]
Novel T cell receptor-STEM T cell immunotherapy in lung cancer
Translational Candidate HLA-A*02 restricted CT83 antigen-specific T cell receptor-engineered T cell cells (CT83TCR-STEM T cells for short). Area of Impact Metastatic lung cancer patients who fail to respond to immune checkpoint therapy or prior treatment Mechanism of Action Despite the impressive clinical response to immune checkpoint inhibitors, the majority of lung cancer patients fail to […]
Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1α
Translational Candidate EGFR-CAR_sIL15 NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells Area of Impact patients with metastatic breast cancer, especially HER2-low breast cancer Mechanism of Action EGFR-CAR_sIL15 NK cells are umbilical cord blood-derived CD34+ HSCs that are engineered to target EGFR and express soluble IL-15, and then are differentiated into NK cells. […]
Next generation affinity-tuned CAR for prostate cancer
Translational Candidate A next generation cell therapy product that targets prostate cancer cells Area of Impact Prostate cancer Mechanism of Action The therapeutic candidate when expressed on the surface of immune cells allow them to binds to a protein that is overexpressed on the prostate cancer cells and kills them. Unmet Medical Need Prostate cancer […]
Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma
Translational Candidate Human T cells transduced with a lentiviral vector encoding anti-EGFRvIII synNotch-primed anti-EphA2/IL-13Rα2 chimeric antigen receptor. Area of Impact Glioblastoma is the most common malignant brain tumor, affecting approximately 3 out of 100,000 people/year in the USA with extremely poor prognosis. Mechanism of Action In our proposed system, the first antigen EGFRvIII, which is […]
CAR-Tnm cell therapy for melanoma targeting TYRP-1
Translational Candidate Autologous naive/memory progenitor T cells genetically modified to express a chimeric antigen receptor targeting the Tyrosinase-related protein 1 Area of Impact Patient with melanoma, without response or with relapse after immune checkpoint blockade therapy and patients with rare melanoma subtypes. Mechanism of Action T cells genetically modified to express the 20D7SL CAR detect […]
Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma
Translational Candidate Human T cells transduced with a lentiviral vector encoding anti-EGFRvIII synNotch-primed anti-EphA2/IL-13Rα2 chimeric antigen receptor. Area of Impact Glioblastoma is the most common malignant brain tumor, affecting approximately 3 out of 100,000 people/year in the USA with extremely poor prognosis. Mechanism of Action In our proposed system, the first antigen EGFRvIII, which is […]
Neural Stem cell-mediated oncolytic immunotherapy for ovarian cancer
Translational Candidate A clinically tested tumor-tropic neural stem cell (NSC) platform for effective distribution of oncolytic virotherapy to ovarian cancer metastases Area of Impact This NSC-delivered virotherapy approach will lead to a more efficacious, less toxic treatment for metastatic ovarian cancer and chemoresistent cells. Mechanism of Action CRAd-S-pk7 is a tumor specific replication-competent adenovirus driven […]
Placental Derived Natural Killer Cells to Target Solid Tumor Cancer Stem Cells (CSC)
Translational Candidate Placental-derived stem cells becoming a unique NK-like cell Area of Impact solid tissue cancers Mechanism of Action These expanded cells share many characteristics as NK cells but appear to represent a unique stage in differentiation and a cell-type with advantageous properties. These cells have been demonstrated to persist for much longer periods of […]
2nd Generation Vaccine for the Treatment of Glioblastoma
Translational Candidate It is the peptide LEEKKYNYVVVTDHC conjugated to KLH and used as an anti-cancer vaccine. Area of Impact This is a better optimized, more robust vaccine that aspires to greatly improve glioblastoma patient survival over the current vaccine. Mechanism of Action The vaccine stimulates B cell and T cells. We have found this may […]